ReviewHealthcare (Basel, Switzerland)2022
Clinical Diagnosis and Early Medical Management for Endometriosis: Consensus from Asian Expert Group.
Review in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A systematic review and Bayesian analysis of the adverse effects of dienogest.BMC pharmacology & toxicology · 2024Pooled it
- Global inequities and fragmentation in guidelines for endometriosis: a scoping review.Communications medicine · 2026Article
- [Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Efficacy and acceptability of dienogest among patients with endometriosis in Thailand.BMC women's health · 2026Observational
- The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS).Reproductive biology and endocrinology : RB&E · 2025Article
- Serum miR-141-3p serves as a biomarker for early-stage diagnosis of endometriosis.BMC medical genomics · 2025Article
- Endometriosis and adenomyosis research priorities in India and Sri Lanka: a call for regional collaboration.The Lancet regional health. Southeast Asia · 2025Review
- Erastin-induced multi-pathway cell death in endometriosis: a mechanistic and translational narrative review.Frontiers in medicine · 2025Review
- MRI classification of uterosacral ligament involvement in endometriosis: the Hôtel-Dieu classification.The British journal of radiology · 2024Article
- Dienogest in conjunction with GnRH-a for postoperative management of endometriosis.Frontiers in pharmacology · 2024Article
- Impact of a quality programme on overindication of surgeries for endometriosis and cholecystectomies.BMJ open quality · 2023Article
- A Cluster Randomised Control Trial of an SMS-Based Intervention to Promote Antenatal Health amongst Pregnant Women in a Remote, Highland Region of Vietnam.Healthcare (Basel, Switzerland) · 2023Article
- The 10 "Cardinal Sins" in the Clinical Diagnosis and Treatment of Endometriosis: A Bayesian Approach.Journal of clinical medicine · 2023Article
- Endometriosis in Adolescents: Diagnostics, Clinical and Laparoscopic Features.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 17 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work provides consensus guidance regarding clinical diagnosis and early medical management of endometriosis within Asia. Clinicians with expertise in endometriosis critically evaluated available evidence on clinical diagnosis and early medical management and their applicability to current clinical practices. Clinical diagnosis should focus on symptom recognition, which can be presumed to be endometriosis without laparoscopic confirmation. Transvaginal sonography can be appropriate for diagnosing pelvic endometriosis in select patients. For early empiric treatment, management of women with clinical presentation suggestive of endometriosis should be individualized and consider presentation and therapeutic need. Medical treatment is recommended to reduce endometriosis-associated pelvic pain for patients with no immediate pregnancy desires. Hormonal treatment can be considered for pelvic pain with a clinical endometriosis diagnosis; progestins are a first-line management option for early medical treatment, with oral progestin-based therapies generally a better option compared with combined oral contraceptives because of their safety profile. Dienogest can be used long-term if needed and a larger evidence base supports dienogest use compared with gonadotropin-releasing hormone agonists (GnRHa) as first-line medical therapy. GnRHa may be considered for first-line therapy in some specific situations or as short-term therapy before dienogest and non-steroidal anti-inflammatory drugs as add-on therapy for endometriosis-associated pelvic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.